Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Decrease of energy expenditure causes weight increase in olanzapine treatment - a case study.

M Virkkunen1, K Wahlbeck, A Rissanen

  • 1Department of Psychiatry, University of Helsinki, Finland. matti.virkkunen@huch.fi

Pharmacopsychiatry
|July 11, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

F13A1 transglutaminase expression in human adipose tissue increases in acquired excess weight and associates with inflammatory status of adipocytes.

International journal of obesity (2005)·2020
Same author

Clinical and organizational factors predicting readmission for mental health patients across Italy.

Social psychiatry and psychiatric epidemiology·2019
Same author

The balance of adult mental health care: provision of core health versus other types of care in eight European countries.

Epidemiology and psychiatric sciences·2018
Same author

Adipose tissue mitochondrial capacity associates with long-term weight loss success.

International journal of obesity (2005)·2017
Same author

Subcutaneous adipose tissue gene expression and DNA methylation respond to both short- and long-term weight loss.

International journal of obesity (2005)·2017
Same author

Physical activity, cardiorespiratory fitness, and metabolic outcomes in monozygotic twin pairs discordant for body mass index.

Scandinavian journal of medicine & science in sports·2017
Same journal

A Tribute to Prof. Jules Angst highlighting his Contributions to Clozapine.

Pharmacopsychiatry·2026
Same journal

Correction: Escitalopram and Clonazepam Affect Gasotransmitter-related Enzyme (nNOS, HO-2, CBS) Gene Expression in the Rat Brain.

Pharmacopsychiatry·2026
Same journal

Correction: Non-Response to Antidepressants: Risk Factors and Therapeutic Possibilities.

Pharmacopsychiatry·2026
Same journal

Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2026 - Pharmacokinetic, pharmacogenetic and clinical aspects.

Pharmacopsychiatry·2026
Same journal

Therapeutic Drug Monitoring of Cannabinoids: Therapeutic Reference Ranges for Delta-9-tetrahydrocannabinol in Medical Cannabis, Nabiximols, Dronabinol and Nabilone.

Pharmacopsychiatry·2026
Same journal

A Naturalistic Study on the Cost Reduction and Efficacy of Long-acting Antipsychotics in an Early Intervention Programme for Patients with Recent-onset Psychosis.

Pharmacopsychiatry·2026
See all related articles

Olanzapine treatment caused significant weight gain in a patient with mental health conditions. Decreased energy expenditure, altered thyroid hormones, and lipid changes may contribute to this side effect.

Area of Science:

  • Pharmacology
  • Metabolic Research
  • Clinical Psychiatry

Background:

  • Atypical antipsychotics like olanzapine are associated with significant weight gain.
  • Understanding the metabolic mechanisms behind olanzapine-induced weight gain is crucial for patient management.

Observation:

  • A 48-year-old male patient with antisocial personality disorder, alcohol dependence, and paranoid ideation was studied.
  • The patient received olanzapine (10-15 mg/day) for one month, during which his weight increased by 6 kg.

Findings:

  • Basal and 3-hour energy expenditure decreased after olanzapine treatment.
  • Serum thyroid hormone and HDL cholesterol levels decreased, while triglyceride and LDL cholesterol levels increased.
  • Insulin sensitivity remained unchanged.

Related Experiment Videos

Implications:

  • Reduced basal energy expenditure appears to be a key factor in olanzapine-associated weight gain.
  • These metabolic alterations highlight the need for monitoring and potential interventions in patients treated with olanzapine.
  • Further research is warranted to explore personalized treatment strategies to mitigate metabolic side effects.